(Q43430617)

English

Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission--experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG).

scientific article published in June 2004

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

23 November 2017

Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission--experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG). (English)

1 reference

Europe PubMed Central

23 November 2017

0 references

phase III clinical trial

0 references

multicenter clinical trial

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

chronic lymphocytic leukemia

1 reference

based on heuristic

inferred from title

author name string

C-M Wendtner

1

1 reference

Europe PubMed Central

23 November 2017

M Ritgen

2

1 reference

Europe PubMed Central

23 November 2017

C D Schweighofer

3

1 reference

Europe PubMed Central

23 November 2017

G Fingerle-Rowson

4

1 reference

Europe PubMed Central

23 November 2017

H Campe

5

1 reference

Europe PubMed Central

23 November 2017

G Jäger

6

1 reference

Europe PubMed Central

23 November 2017

B Eichhorst

7

1 reference

Europe PubMed Central

23 November 2017

R Busch

8

1 reference

Europe PubMed Central

23 November 2017

H Diem

9

1 reference

Europe PubMed Central

23 November 2017

A Engert

10

1 reference

Europe PubMed Central

23 November 2017

S Stilgenbauer

11

1 reference

Europe PubMed Central

23 November 2017

H Döhner

12

1 reference

Europe PubMed Central

23 November 2017

M Kneba

13

1 reference

Europe PubMed Central

23 November 2017

B Emmerich

14

1 reference

Europe PubMed Central

23 November 2017

M Hallek

15

1 reference

Europe PubMed Central

23 November 2017

German CLL Study Group (GCLLSG)

16

1 reference

Europe PubMed Central

23 November 2017

publication date

1 June 2004

1 reference

Europe PubMed Central

23 November 2017

1 reference

Europe PubMed Central

23 November 2017

18

1 reference

Europe PubMed Central

23 November 2017

1093-1101

1 reference

Europe PubMed Central

23 November 2017

6

1 reference

Europe PubMed Central

23 November 2017

https://scigraph.springernature.com/pub.10.1038/sj.leu.2403354

0 references

Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403354

21 January 2018

Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403354

21 January 2018

Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403354

21 January 2018

Autologous and allogeneic stem cell transplantation for chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403354

21 January 2018

Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712).

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403354

21 January 2018

Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403354

21 January 2018

Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403354

21 January 2018

Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL).

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403354

21 January 2018

Reshaping human antibodies for therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403354

21 January 2018

Common toxicity criteria: version 2.0. an improved reference for grading the acute effects of cancer treatment: impact on radiotherapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403354

21 January 2018

Genomic aberrations and survival in chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403354

21 January 2018

T-cell epitope mapping by flow cytometry

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403354

21 January 2018

Determination of antigen-specific memory/effector CD4+ T cell frequencies by flow cytometry: evidence for a novel, antigen-specific homeostatic mechanism in HIV-associated immunodeficiency

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403354

21 January 2018

Population coverage by HLA class-I restricted cytotoxic T-lymphocyte epitopes.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403354

21 January 2018

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403354

21 January 2018

Analysis of survival by tumor response.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403354

21 January 2018

Cytomegalovirus viremia during Campath-1H therapy for relapsed and refractory chronic lymphocytic leukemia and prolymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403354

21 January 2018

Infectious complications in chronic lymphocytic leukaemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403354

21 January 2018

Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403354

21 January 2018

Antibody selection against CD52 produces a paroxysmal nocturnal haemoglobinuria phenotype in human lymphocytes by a novel mechanism

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403354

21 January 2018

The PNH phenotype cells that emerge in most patients after CAMPATH-1H therapy are present prior to treatment.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403354

21 January 2018

Bone marrow biopsy in hemophagocytic syndrome

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403354

21 January 2018

Prognostic significance of quantitative analysis of WT1 gene transcripts by competitive reverse transcription polymerase chain reaction in acute leukaemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403354

21 January 2018

Molecular monitoring of response to imatinib (Glivec) in CML patients pretreated with interferon alpha. Low levels of residual disease are associated with continuous remission

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403354

21 January 2018

Serial minimal residual disease (MRD) analysis as a predictor of response duration in Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL) during imatinib treatment

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403354

21 January 2018

Pharmacokinetics of CAMPATH-1H: assay development and validation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403354

21 January 2018

Humanized CD52 monoclonal antibody campath-1H as first-line treatment in chronic lymphocytic leukaemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403354

21 January 2018

REMISSION INDUCTION IN NON-HODGKIN LYMPHOMA WITH RESHAPED HUMAN MONOCLONAL ANTIBODY CAMPATH-1H

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403354

7 January 2021

based on heuristic

inferred from DOI database lookup

CAMPATH-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin's lymphomas: a phase II multicenter study. European Study Group of CAMPATH-1H Treatment in Low-Grade Non-Hodgkin's Lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403354

7 January 2021

based on heuristic

inferred from DOI database lookup

In vivo 'Purging' of residual disease in CLL with Campath-1H

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403354

7 January 2021

based on heuristic

inferred from DOI database lookup

Ex vivo T-cell depletion with the monoclonal antibody Campath-1 plus human complement effectively prevents acute graft-versus-host disease in allogeneic bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403354

7 January 2021

based on heuristic

inferred from DOI database lookup

Structural motifs involved in human IgG antibody effector functions

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403354

7 January 2021

based on heuristic

inferred from DOI database lookup

Improved assessment of minimal residual disease in B cell malignancies using fluorogenic consensus probes for real-time quantitative PCR

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403354

7 January 2021

based on heuristic

inferred from DOI database lookup

High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath-1H in delaying immune reconstitution

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403354

7 January 2021

based on heuristic

inferred from DOI database lookup

A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403354

7 January 2021

based on heuristic

inferred from DOI database lookup

Pharmacokinetics of CAMPATH-1H in BMT patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403354

7 January 2021

based on heuristic

inferred from DOI database lookup

Single-Agent Rituximab as First-Line and Maintenance Treatment for Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma: A Phase II Trial of the Minnie Pearl Cancer Research Network

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403354

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/SJ.LEU.2403354

1 reference

Europe PubMed Central

23 November 2017

Dimensions Publication ID

0 references

1 reference

Europe PubMed Central

23 November 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43430617&oldid=1612725509"